111 (NASDAQ:YI – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Insider & Institutional Ownership
21.3% of 111 shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Comparatively, 9.4% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares 111 and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 111 | -0.53% | N/A | -2.72% |
| 10x Genomics | -6.77% | -6.89% | -5.34% |
Risk and Volatility
Analyst Recommendations
This is a breakdown of current ratings for 111 and 10x Genomics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
| 10x Genomics | 2 | 10 | 5 | 0 | 2.18 |
10x Genomics has a consensus target price of $19.46, indicating a potential downside of 22.88%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts clearly believe 10x Genomics is more favorable than 111.
Earnings & Valuation
This table compares 111 and 10x Genomics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 111 | $1.80 billion | 0.03 | -$2.48 million | ($1.00) | -6.67 |
| 10x Genomics | $642.82 million | 5.02 | -$43.54 million | ($0.35) | -72.11 |
111 has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
